Beta Bionics (BBNX) Liabilities and Shareholders Equity (2023 - 2026)

Beta Bionics has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $292.4 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 11.39% year-over-year to $292.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.3 billion (up 53.56% YoY) and the FY2025 annual result came in at $328.7 million, up 119.68% from the prior year.
• Liabilities and Shareholders Equity fell to $292.4 million in Q2 2026 per BBNX's latest filing, from $304.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $338.0 million in Q1 2025 and troughed at $110.0 million in Q4 2023.
• A 4-year average of $272.9 million and a median of $316.6 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity soared 119.68% in 2025, then declined 11.39% in 2026.
• Over 4 years, Liabilities and Shareholders Equity stood at $110.0 million in 2023, then surged by 35.99% to $149.6 million in 2024, then jumped by 119.68% to $328.7 million in 2025, then retreated by 11.06% to $292.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $292.4 million, $304.4 million, and $328.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.